How does SNGX's PS Ratio compare to its peers?

SNGX is expensive based on its Price-To-Sales Ratio (22.8x) compared to the peer average (9.3x).

How does SNGX's PS Ratio compare vs other companies in the US Biotechs Industry?

SNGX is expensive based on its Price-To-Sales Ratio (22.8x) compared to the US Biotechs industry average (9.6x).

What is SNGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNGX is expensive based on its Price-To-Sales Ratio (22.8x) compared to the estimated Fair Price-To-Sales Ratio (8.5x).

What is the Fair Price of SNGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate SNGX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine [[statistical confidence]] in agreement.

Soligenix (Nasdaq:SNGX) - Stock Price, News & Analysis

SNGX Stock Overview

A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. More details

SNGX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 44.23% per year

Earnings have grown 11.4% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap ($8M)

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 12.1% per year for the next 3 years

Makes less than USD$1m in revenue ($364K)

+ 2 more risks

Soligenix, Inc. Competitors

Ensysce Biosciences

NasdaqCM:ENSC

US$11.6m

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Vaccinex

NasdaqCM:VCNX

US$10.1m

Eagle Pharmaceuticals

OTCPK:EGRX

US$11.7m

Price History & Performance

Summary of all time highs, changes and price drops for Soligenix
Historical stock prices
Current Share Price	US$3.31
52 Week High	US$32.00
52 Week Low	US$1.83
Beta	1.85
11 Month Change	-7.54%
3 Month Change	-19.07%
1 Year Change	-48.86%
33 Year Change	-98.46%
5 Year Change	-98.62%
Change since IPO	-99.99%

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16

Shareholder Returns

	SNGX	US Biotechs	US Market
7D	-6.5%	-3.7%	0.3%
1Y	-48.9%	15.2%	31.1%

Return vs Industry: SNGX underperformed the US Biotechs industry which returned 15.2% over the past year.

Return vs Market: SNGX underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is SNGX's price volatile compared to industry and market?
SNGX volatility
SNGX Average Weekly Movement	13.8%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SNGX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SNGX's weekly volatility has decreased from 46% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1987	14	Christopher Schaber	www.soligenix.com

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.

Soligenix, Inc. Fundamentals Summary

How do Soligenix's earnings and revenue compare to its market cap?
SNGX fundamental statistics
Market cap	US$8.43m
Earnings (TTM)	-US$7.10m
Revenue (TTM)	US$364.18k

22.8x

P/S Ratio

-1.2x

P/E Ratio

Is SNGX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SNGX income statement (TTM)
Revenue	US$364.18k
Cost of Revenue	US$340.92k
Gross Profit	US$23.27k
Other Expenses	US$7.12m
Earnings	-US$7.10m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.83
Gross Margin	6.39%
Net Profit Margin	-1,949.32%
Debt/Equity Ratio	34.7%

How did SNGX perform over the long term?

See historical performance and comparison

SNGX Stock Overview

Rewards

Risk Analysis

Soligenix, Inc. Competitors

NasdaqCM:ENSC

US$11.6m

NasdaqCM:VBLT

US$12.1m

NasdaqCM:VCNX

US$10.1m

OTCPK:EGRX

US$11.7m

Price History & Performance

Recent News & Updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 13% to US$35.00

Recent updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 13% to US$35.00

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 29% to US$2.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Consensus EPS estimates upgraded to US$0.63 loss

Price target increased by 7.7% to US$3.50

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Consensus revenue estimates decrease by 11%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

New major risk - Share price stability

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Consensus EPS estimates upgraded to US$0.83 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 35% to US$3.25

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Consensus revenue estimates increase by 13%

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

No longer forecast to breakeven

Consensus revenue estimates decrease by 76%, EPS upgraded

No longer forecast to breakeven

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations